Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress

Critical Care Medicine

Volumn 37, Issue 1, 2009, Pages 246-255

  Nacira, Sennoun ^a   Meziani, Ferhat ^b,d   Dessebe, Olivier ^a   Cattan, Valérie ^a   Collin, Solène ^a   Montemont, Chantal ^a   Gibot, Sebastien ^a   Asfar, Pierre ^c,d   Ramaroson, Andriantsitohaina ^b   Regnault, Veronique ^a   Slama, Michel ^e   Lecompte, Thomas ^a   Lacolley, Patrick ^a   Levy, Bruno ^a  

^a INSERM   (France)

^b Universite d'Angers   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Activated protein C; Antioxidants; Catecholamines; Nitric oxide; Shock

Indexed keywords

DROTRECOGIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; NITRIC OXIDE; SODIUM CHLORIDE; SUPEROXIDE; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL PROTECTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; HEART; HEART MUSCLE BLOOD FLOW; HEART PROTECTION; HEMODYNAMIC PARAMETERS; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ACTIVATION; MALE; NONHUMAN; OXIDATIVE STRESS; OXYGEN TENSION; PRIORITY JOURNAL; RAT; SEPTIC SHOCK; SPIN TRAPPING; UPREGULATION; VASCULAR RESISTANCE; WESTERN BLOTTING; ANIMAL; BLOOD VESSEL; DRUG EFFECT; ENDOTOXEMIA; HEART MUSCLE; IMMUNOLOGY; METABOLISM; WISTAR RAT;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOOD VESSELS; ENDOTOXEMIA; HEART; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MYOCARDIUM; OXIDATIVE STRESS; PROTEIN C; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SHOCK, SEPTIC;

EID: 59649124331     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318192fe4f     Document Type: Article

References (51)

1. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365:63-78
2. Remick DG. Pathophysiology of sepsis. Am J Pathol 2007; 170:1435-1444
3. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35:1599-1608
4. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87:315-424
5. Rossi MA, Celes MR, Prado CM, et al. Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. Shock 2007; 27:10-18
6. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
7. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161-3172
8. Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13:382-385
9. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276:11199-11203
10. White B, Schmidt M, Murphy C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110:130-134
11. Bilbault P, Lavaux T, Launoy A, et al Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/ Bcl-xl ratios in circulating mononuclear cells: A cohort study in septic shock patients. Crit Care Med 2007; 35:69-75
12. Yamaji K, Wang Y, Liu Y, et al. Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation. Thromb Res 2005; 115: 319-325
13. Looney MR, Matthay MA. Bench-to-bedside review: The role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury. Crit Care 2006; 10:239
14. Regnault V, Levy B. Recombinant activated protein C in sepsis: endothelium protection or endothelium therapy? Crit Care 2007; 11: 103
15. Favory R, Lancel S, Marechal X, et al. Cardiovascular protective role for activated protein C during endotoxemia in rats. Intensive Care Med 2006; 32:899-905
16. Isobe H, Okajima K, Uchiba M, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001; 104:1171-1175
17. Gupta A, Berg DT, Gerlitz B, et al Activated Protein C Suppresses Adrenomedullin and Ameliorates Lipopolysaccharide-Induced Hypotension. Shock 2007; 28:468-476
18. Wang Z, Su F, Rogiers P, et al Beneficial effects of recombinant human activated protein C in a ewe model of septic shock*. Crit Care Med 2007; 35:2594-2600
19. Monnet X, Lamia B, Anguel N, et al. Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 2005; 31:1573-1576
20. Cuenca J, Martin-Sanz P, Alvarez-Barrientos AM, et al. Infiltration of inflammatory cells plays an important role in matrix metallo-proteinase expression and activation in the heart during sepsis. Am J Pathol 2006; 169: 1567-1576
21. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152:189-205
22. Lancel S, Tissier S, Mordon S, et al. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J Am Coll Cardiol 2004; 43:2348-2358
23. Ralay Ranaivo H, Carusio N, Wangensteen R, et al. Protection against endotoxic shock as a consequence of reduced nitrosative stress in MLCK210-null mice. Am J Pathol 2007; 170: 43-46
24. Miller FJ, Jr, Gutterman DD, Rios CD, et al. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998; 82:1298-1305
25. Sennoun N, Montemont C, Gibot S, et al. Comparative effects of early versus delayed use of norepinephrine in resuscitated endotoxic shock. Crit Care Med 2007; 35: 1736-1740
26. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161-3172
27. Gupta A, Rhodes GJ, Berg DT, et al Activated Protein C ameliorates LPS-induced acute kidney injury and down-regulates renal iNOS and Angiotensin 2. Am J Physiol Renal Physiol 2007; 293:F245-254
28. Macias WL, Yan SB, Williams MD, et al New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005; 9Suppl 4:S38-45
29. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-595
30. Szabo C, Mitchell JA, Thiemermann C, et al. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 1993; 108:786-792
31. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun 1993; 18:195-199
32. Soriano FG, Liaudet L, Szabo E, et al. Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock 2002; 17:286-292
33. John J, Awab A, Norman D, et al. Activated protein C improves survival in severe sepsis patients with elevated troponin. Intensive Care Med 2007; 33:2122-2128
34. Merx MW, Weber C. Sepsis and the heart. Circulation 2007; 116:793-802
35. Rastaldo R, Pagliaro P, Cappello S, et al. Nitric oxide and cardiac function. Life Sci 2007; 81:779-793
36. Decking UK, Flesche CW, Godecke A, et al. Endotoxin-induced contractile dysfunction in guinea pig hearts is not mediated by nitric oxide. Am J Physiol 1995; 268(6 Pt 2): H2460-2465
37. Suliman HB, Welty-Wolf KE, Carraway M, et al. Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis. Cardiovasc Res 2004; 64:279-288
38. Echtay KS, Roussel D, St-Pierre J, et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002; 415:96-99
39. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360:219-223
40. Mizutani A, Okajima K, Uchiba M, et al. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95: 3781-3787
41. Hoffmann JN, Vollmar B, Laschke MW, et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004; 32: 1011-1017
42. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90:251-262
43. Lalu MM, Csont T, Schulz R. Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. Crit Care Med 2004; 32:1332-1337
44. Chen J, Tung CH, Allport JR, et al. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 2005; 111:1800-1805
45. Poon BY, Raharjo E, Patel KD, et al. Complexity of inducible nitric oxide synthase: cellular source determines benefit versus toxicity. Circulation 2003; 108:1107-1112
46. Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102:1499-1505
47. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204:2439-2448
48. Griffin JH, Fernandez JA, Mosnier LO, et al. The promise of protein C. Blood Cells Mol Dis 2006; 36:211-216
49. Remick DG, Ward PA. Evaluation of endotoxin models for the study of sepsis. Shock 2005; 24Suppl 1:7-11
50. Vieillard-Baron A, Prin S, Chergui K, et al. Hemodynamic instability in sepsis: bedside assessment by Doppler echocardiography. Am J Respir Crit Care Med 2003; 168: 1270-1276
51. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377